EverGlade Consulting in the Media

EverGlade Consulting, a market leader in delivering strategic solutions and services, announced today that its philanthropic arm, EverGladeCares, has choosen Big Brothers Big Sisters of the Lowcountry as its first area of support.

EverGlade Consulting, a trusted leader in strategic problem-solving and innovative solutions, has always been committed to building a better future, not just for our clients but for society at large. In this spirit, our corporate social responsibility arm, EverGladeCares, has evolved its focus to address new emerging needs. 

The Biomedical Advanced Research and Development Authority (BARDA) has recently released a modernized Broad Agency Announcement (BAA) updated to include new and revised areas of interest (AOIs) for the development of medical countermeasures (MCMs), including vaccines, drugs, therapies, and diagnostic tools. The new AOIs include the following:

The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined as nuclear, chemical, and/or biological weapons.

 In a move to secure America’s leadership in the semiconductor sector, the U.S. Department of Commerce (DoC) announced on Friday, the start of its rolling pre-application process for large-scale supply chain projects and wafer manufacturing facilities.

 In response to the increasing complexity of the space environment, the Defense Innovation Unit (DIU), has announced its pursuit of innovative commercial solutions for the development of Tactically Responsive Space (TacRS) systems.

The Biden Cancer Moonshot has announced a pioneering program under the Advanced Research Projects Agency for Health (ARPA-H) to develop innovative technologies to enhance the precision and accuracy of tumor removal in cancer surgeries.

Eric Jia-Sobota, Founder of EverGlade Consulting (“EverGlade”), is excited to announce a significant shift in EverGlade’s marketing strategy and the launch of a new advertising campaign.

The National Institute of Allergy and Infectious Diseases (NIAID) recently released a Notice of Special Interest (NOSI) aimed at encouraging research proposals on targeted protein and nonprotein degradation for the development of anti-infective strategies against viral, bacterial, and fungal pathogens and toxins. 

As EverGlade Consulting passes its three-year milestone, supplier diversity is quickly becoming the cornerstone to a new era of diversity, equity, and inclusion in today’s evolving business ecosystem. Visibility and representation have been shown to be marked characteristics that foster more inclusivity and advance equitable agendas within businesses, organizations, and even governmental entities.

The Fiscal Responsibility Act of 2023 aims to reduce USG spending by $2.1 trillion, with an additional $1.5 trillion in mandated savings over the next two years. The bill reclaims $28 billion of unutilized COVID-19 funds and cuts an additional $400 million from the CDC’s “Global Health Fund,” which channels taxpayer funds to China. Collectively, these cuts represent the largest rollback of federal spending in American history.

In the latest amendment to its Broad Agency Announcement (BAA), BARDA (Biomedical Advanced Research and Development Authority) is seeking proposals for the development of cost-effective and adaptable therapeutic platforms to treat viral infections, as well as next-generation COVID-19 vaccines.